CAJ | 학술논문

非布司他是一种新型选择性黄嘌呤氧化酶抑制剂，主要用于具有痛风症状的高尿酸血症患者的治疗。非布司他的推荐起始剂量为40 mg，1次/d。目前尚无充分依据证实非布司他降尿酸的临床疗效优于别嘌醇，但有研究提示在合并糖尿病或年龄≥65岁的痛风患者中，非布司他80 mg/d组的治疗效果更佳。非布司他常见的不良反应包括肝功能异常、腹泻、头痛、恶心及皮疹等，心血管系统不良反应与别嘌醇比较尚未发现差异有统计学意义。
비포사타시일충신형선택성황표령양화매억제제，주요용우구유통풍증상적고뇨산혈증환자적치료。비포사타적추천기시제량위40 mg，1차/d。목전상무충분의거증실비포사타강뇨산적림상료효우우별표순，단유연구제시재합병당뇨병혹년령≥65세적통풍환자중，비포사타80 mg/d조적치료효과경가。비포사타상견적불량반응포괄간공능이상、복사、두통、악심급피진등，심혈관계통불량반응여별표순비교상미발현차이유통계학의의。
Febuxostat is a new type of selective xanthine oxidase inhibitor,which mainly be used for the treatment of hyperuricemia patients with gout symptoms. The recommended initial dose of febuxostat is 40 mg once daily. In the present,there is no sufficient evidence to demonstrate that the clinical effects of febuxostat in reducing the uric acid are better than that of allopurinol. However,it is reported that febuxostat in 80 mg has better treatment effects in gout patients with diabetes or≥65 years old. The common adverse reactions of febuxostat are liver dysfunction,diarrhea,headache,nausea,rash,and so on. The differences of adverse reactions in cardiovascular system between febuxostat and allopurinol are not statistically significant.